Adam Kresak

970 total citations
32 papers, 676 citations indexed

About

Adam Kresak is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Adam Kresak has authored 32 papers receiving a total of 676 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Adam Kresak's work include Lung Cancer Research Studies (8 papers), Esophageal Cancer Research and Treatment (5 papers) and Neuroendocrine Tumor Research Advances (5 papers). Adam Kresak is often cited by papers focused on Lung Cancer Research Studies (8 papers), Esophageal Cancer Research and Treatment (5 papers) and Neuroendocrine Tumor Research Advances (5 papers). Adam Kresak collaborates with scholars based in United States, Ghana and France. Adam Kresak's co-authors include Gary Wildey, Afshin Dowlati, Michael Yang, Pingfu Fu, Karen McColl, Mary Beth Lipka, Yanwen Chen, Xueming Wu, Zheng‐Rong Lu and Mark A. Griswold and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

In The Last Decade

Adam Kresak

29 papers receiving 672 citations

Peers

Adam Kresak
Caio Max S. Rocha Lima United States
Hanako Sato Japan
Xinmin Zhao China
Minsig Choi United States
Daniela Morales-Espinosa Spain
Enrique Grande Pulido Spain
Giulia Orsi Italy
Masayuki Otsuka Japan
Nancy Paz United States
Zhongzhen Guan China
Caio Max S. Rocha Lima United States
Adam Kresak
Citations per year, relative to Adam Kresak Adam Kresak (= 1×) peers Caio Max S. Rocha Lima

Countries citing papers authored by Adam Kresak

Since Specialization
Citations

This map shows the geographic impact of Adam Kresak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Kresak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Kresak more than expected).

Fields of papers citing papers by Adam Kresak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Kresak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Kresak. The network helps show where Adam Kresak may publish in the future.

Co-authorship network of co-authors of Adam Kresak

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Kresak. A scholar is included among the top collaborators of Adam Kresak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Kresak. Adam Kresak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Han, Ali Reza Rezvani, Karen McColl, et al.. (2025). Assessment of targets of antibody drug conjugates in SCLC. npj Precision Oncology. 9(1). 1–1. 12 indexed citations
2.
3.
4.
5.
Singh, Salendra, Amitabh Chak, David G. Beer, et al.. (2023). Discovery and Initial Characterization of Long Intergenic Noncoding RNAs Associated With Esophageal Adenocarcinoma. Gastroenterology. 165(2). 505–508.e7. 2 indexed citations
6.
Kresak, Adam, Howard Meyerson, Christopher B. Ryder, et al.. (2023). IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1‐like B‐acute lymphoblastic leukaemia. British Journal of Haematology. 204(1). 229–239. 1 indexed citations
7.
Wildey, Gary, Karen McColl, Mohammad A. Shatat, et al.. (2022). Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer. Molecular Cancer Therapeutics. 22(2). 264–273. 18 indexed citations
8.
Joseph, Peronne, Salendra Singh, Adam Kresak, et al.. (2022). The Ephrin B2 Receptor Tyrosine Kinase Is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett’s Neoplasia. Gastroenterology. 163(5). 1228–1241. 12 indexed citations
9.
Blum, Andrew E., Salendra Singh, Adam Kresak, et al.. (2022). HNF4A Defines Molecular Subtypes and Vulnerability to Transforming Growth Factor β-Pathway Targeted Therapies in Cancers of the Distal Esophagus. Gastroenterology. 163(5). 1457–1460. 3 indexed citations
10.
Tian, He, Gary Wildey, Karen McColl, et al.. (2020). Identification of RUNX1T1 as a potential epigenetic modifier in small‐cell lung cancer. Molecular Oncology. 15(1). 195–209. 7 indexed citations
11.
Blum, Andrew E., Lakshmeswari Ravi, Adam Kresak, et al.. (2019). Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor-β and JNK Signaling Pathways in Esophageal Cancer. Gastroenterology. 156(6). 1761–1774. 36 indexed citations
12.
Cummings, Linda C., Prashanthi N. Thota, Joseph Willis, et al.. (2017). A nonrandomized trial of vitamin D supplementation for Barrett’s esophagus. PLoS ONE. 12(9). e0184928–e0184928. 9 indexed citations
13.
Dowlati, Afshin, Mary Beth Lipka, Karen McColl, et al.. (2016). Clinical correlation of extensive-stage small-cell lung cancer genomics. Annals of Oncology. 27(4). 642–647. 69 indexed citations
14.
Babakoohi, Shahab, Amy Kluge, James J. Morrow, et al.. (2014). RET Mutation and Expression in Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(9). 1316–1323. 38 indexed citations
15.
Fink, Stephen P., Dawn Dawson, Yongyou Zhang, et al.. (2014). Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs. Carcinogenesis. 36(2). 291–298. 13 indexed citations
16.
Greer, Katarina B., et al.. (2013). Insulin/Insulin-Like Growth Factor-1 Pathway in Barrett's Carcinogenesis. Clinical and Translational Gastroenterology. 4(3). e31–e31. 12 indexed citations
17.
Zhou, Zhuxian, Xueming Wu, Adam Kresak, Mark A. Griswold, & Zheng‐Rong Lu. (2013). Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI. Biomaterials. 34(31). 7683–7693. 69 indexed citations
18.
Kunos, Charles A., Tomas Radivoyevitch, Adam Kresak, et al.. (2012). Elevated Ribonucleotide Reductase Levels Associate With Suppressed Radio chemotherapy Response in Human Cervical Cancers. International Journal of Gynecological Cancer. 22(9). 1463–1469. 20 indexed citations
19.
Fan, Weiwen, Zhe Tang, Lihong Yin, et al.. (2011). MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents. Cancer Research. 71(13). 4494–4505. 59 indexed citations
20.
Ogba, Ndiya, et al.. (2011). HEXIM1 is a critical determinant of the response to tamoxifen. Oncogene. 30(33). 3563–3569. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Caio Max S. Rocha Lima Breakdown of academic impact, for papers by Hanako Sato Breakdown of academic impact, for papers by Xinmin Zhao Breakdown of academic impact, for papers by Minsig Choi Breakdown of academic impact, for papers by Daniela Morales-Espinosa Breakdown of academic impact, for papers by Enrique Grande Pulido Breakdown of academic impact, for papers by Giulia Orsi Breakdown of academic impact, for papers by Masayuki Otsuka Breakdown of academic impact, for papers by Nancy Paz Breakdown of academic impact, for papers by Zhongzhen Guan
Rankless by CCL
2026